Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 3475926, 20 pages
https://doi.org/10.1155/2017/3475926
Review Article

HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs

Terasaki Foundation Laboratory, 11570 W. Olympic Blvd., Los Angeles, CA 90064, USA

Correspondence should be addressed to Mepur H. Ravindranath; gro.balikasaret@hmivaR

Received 20 December 2016; Revised 18 March 2017; Accepted 23 March 2017; Published 28 May 2017

Academic Editor: Kurt Blaser

Copyright © 2017 Mepur H. Ravindranath. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. I. Terasaki, “Humoral theory of transplantation,” American Journal of Transplantation, vol. 3, no. 6, pp. 665–673, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Kissmeyer-Nielsen, S. Olsen, V. P. Petersen, and O. Fjeldborg, “Hyperacute rejection of kidney allografts, associated with pre-existing humoral Abs against donor cells,” Lancet, vol. 2, no. 7465, pp. 662–665, 1966. View at Google Scholar
  3. J. M. Cecka, A. Y. Kucheryavayab, N. L. Reinsmoenc, and M. S. Leffelld, “Calculated PRA: initial results show benefits for the sensitized patients and a reduction in positive crossmatches,” American Journal of Transplantation, vol. 11, no. 4, pp. 719–724, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. J. M. Cecka, Q. Zhang, and E. F. Reed, “Preformed cytotoxic Abs in potential allograft recipients: recent data,” Human Immunology, vol. 66, no. 4, pp. 343–349, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. A. Zachary and M. S. Leffell, “HLA mismatching strategies for solid organ transplantation – a balancing act,” Fronteers in Immunology, vol. 7, article 575, pp. 1–14, 2016. View at Publisher · View at Google Scholar
  6. P. I. Terasaki and M. Ozawa, “Predicting kidney graft failure by HLA Abs: a prospective trial,” American Journal of Transplantation, vol. 4, no. 3, pp. 438–443, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Varnavidou-Nicolaidou, A. G. Iniotaki-Theodoraki, I. I. Doxiadis et al., “Expansion of humoral donor-specific alloreactivity after renal transplantation correlates with impaired graft outcome,” Human Immunology, vol. 66, no. 9, pp. 985–988, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Cai, P. I. Terasaki, Q. Mao et al., “Development of nondonor-specific HLA-DR Abs in allograft recipients is associated with shared epitopes with mismatched donor DR antigens,” American Journal of Transplantation, vol. 6, no. 12, pp. 2947–2954, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Hourmant, A. Cesbron-Gautier, P. I. Terasaki et al., “Frequency and clinical implications of development of donor-specific and non-donor-specific HLA Abs after kidney transplantation,” Journal of American Society of Nephrology, vol. 16, no. 9, pp. 2804–2812, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. I. Terasaki, M. Ozawa, and R. Castro, “Four-year follow-up of a prospective trial of HLA and MICA Abs on kidney graft survival,” American Journal of Transplantation, vol. 7, no. 2, pp. 408–415, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Süsal, D. Wettstein, B. Döhler et al., “Collaborative transplant study report. Association of kidney graft loss with de novo produced donor-specific and non-donor-specific HLA Abs detected by single antigen testing,” Transplantation, vol. 99, no. 9, pp. 1976–1980, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Michel, R. Santella, J. Steers et al., “Many de novo donor-specific Abs recognize β2-microglobulin-free, but not intact HLA heterodimers,” HLA, vol. 87, no. 5, pp. 356–366, 2016. View at Publisher · View at Google Scholar
  13. M. H. Ravindranath, T. Pham, M. Ozawa, and P. I. Terasaki, “Abs to HLA-E may account for the non-donor-specific anti-HLA class-Ia Abs in renal and liver transplant recipients,” International Journal of Immunology, vol. 24, no. 1, pp. 43–57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Yard, M. Spruyt-Gerritse, F. Claas et al., “The clinical significance of allospecific Abs against EC cells detected with an Ab-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation,” Transplantation, vol. 55, no. 6, pp. 1287–1293, 1993. View at Publisher · View at Google Scholar
  15. L. A. Michielsen, A. D. van Zuilen, M. M. Krebber, M. C. Verhaar, and H. G. Otten, “Clinical value of non-HLA Abs in kidney transplantation: still an enigma?” Transplantation Review (Orlando), vol. 30, no. 4, pp. 195–202, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. Q. Zhang and E. F. Reed, “The importance of non-HLA Abs in transplantation,” Nature Review Nephrology, vol. 2, no. 8, pp. 484–495, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Delville, B. Charreau, M. Rabant, C. Legendre, and D. Anglicheau, “Pathogenesis of non-HLA Abs in solid organ transplantation: where do we stand?” Human Immunology, vol. 77, no. 11, pp. 1055–1062, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Dragun, R. Catar, and A. Philippe, “Non-HLA Abs against EC targets bridging allo- and autoimmunity,” Kidney International, vol. 90, no. 2, pp. 280–288, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Ippoliti, M. Lucioni, G. Leonardi, and M. Paulli, “Immunomodulation with rabbit anti-thymocyte globulin in solid organ transplantation,” World Journal of Transplantation, vol. 5, no. 4, pp. 261–266, 2015. View at Publisher · View at Google Scholar
  20. D. Glotz, J. P. Haymann, N. Sansonetti et al., “Suppression of HLA-specific alloAbs by high dose intravenous immunogloubulins (IvIg),” Transplantation, vol. 56, no. 2, pp. 335–337, 1993. View at Publisher · View at Google Scholar
  21. D. Glotz, C. Antoine, J. P. Haymann, P. Julia, A. Doboust, and J. Bariety, “Intravenous immunogloubulins and kidney transplantation in patients with anti-HLA antibodies,” Advances in Nephrology from the Necker Hospital, vol. 30, pp. 221–233, 2000. View at Publisher · View at Google Scholar
  22. D. B. Tyan, V. A. Li, L. Czer, A. Trento, and S. C. Jordan, “Intravenous immunoglobulin suppression of HLA alloAb in highly sensitized transplant candidates and transplantation with a histoincompatible organ,” Transplantation, vol. 57, no. 4, pp. 553–562, 1994. View at Publisher · View at Google Scholar
  23. S. C. Jordan, A. W. Quartel, and L. S. Czer, “Posttransplant therapy using high-dose human IVIG to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanisms of action,” Transplantation, vol. 66, no. 6, pp. 800–805, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. R. A. Montgomery, A. A. Zachary, and I. C. Racusen, “Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients,” Transplantation, vol. 70, no. 6, pp. 887–895, 2000. View at Publisher · View at Google Scholar
  25. A. A. Vo, J. Choi, K. Cisneros et al., “Benefits of rituximab combine with intravenous immunoglobulin for desensitization of kidney transplant recipients,” Transplantation, vol. 98, no. 3, pp. 312–319, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. S. V. Onrust, H. M. Lamb, and J. A. Balfour, “Rituximab,” Drugs, vol. 58, no. 1, pp. 79–88, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Levings, R. Sangregorio, and M. G. Roncarolo, “Human CD25+CD4+ T regulatory cells suppress naive and memory T-cell proliferation and can be expanded in vitro without loss of function,” Journal of Experimental Medicine, vol. 193, no. 11, pp. 1295–1301, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. A. van Maurik, K. J. Wood, and N. Jones, “Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T-cell-mediated graft rejection: implications for anti-CD154 immunotherapy,” Journal of Immunology, vol. 169, no. 10, pp. 5401–5404, 2002. View at Publisher · View at Google Scholar
  29. C. Y. Lin, L. Graca, S. P. Cobbold, and H. Waldmann, “Dominant transplantation tolerance impairs CD8+ T-cell function but not expansion,” Nature Immunology, vol. 3, no. 12, pp. 1208–1213, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Baecher-Allan, J. Brown, G. Freeman, and D. A. Hafler, “CD4+CD25+ high regulatory cells in human peripheral blood,” Journal of Immunology, vol. 167, no. 3, pp. 1245–1253, 2001. View at Publisher · View at Google Scholar
  31. W. F. Ng, P. J. Duggan, F. Ponchel et al., “Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells,” Blood, vol. 98, no. 9, pp. 2736–2744, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Hara, C. I. Kingsley, M. Niimi et al., “IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo,” Journal of Immunology, vol. 166, no. 6, pp. 3789–3796, 2001. View at Publisher · View at Google Scholar
  33. L. Graca, S. P. Cobbold, and H. Waldmann, “Identification of regulatory T cells in tolerated allografts,” Journal of Experimental Medicine, vol. 195, no. 12, pp. 1641–1646, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. S. P. Cobbold and H. Waldmann, “Regulatory cells and transplantation tolerance,” Cold Spring Harbor Perspectives in Medicine, vol. 3, no. 6, pp. 1–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Amran, H. Renz, G. Lack, K. Bradley, and E. W. Gelfand, “Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin,” Clinical Immunology Immunopathology, vol. 3, no. 2, pp. 180–186, 1994. View at Google Scholar
  36. H. F. MacMillan, T. Lee, and A. C. Issekutz, “Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation,” Clinical Immunology, vol. 132, no. 2, pp. 222–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Kaveri, T. Vassilev, V. Hurez et al., “Abs to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulinfor therapeutic use,” Journal of Clinical Investigation, vol. 97, no. 3, pp. 865–869, 1996. View at Publisher · View at Google Scholar
  38. N. K. Prasad, G. Papoff, A. Zeuner et al., “Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway,” Journal of Immunology, vol. 161, no. 7, pp. 3781–3790, 1998. View at Google Scholar
  39. A. Ephrem, S. Chamat, C. Miquel et al., “Expansion of CD4+CD25+regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis,” Blood, vol. 111, no. 2, pp. 715–722, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Sundblad, F. Huetz, D. Portnoi, and A. Coutinho, “Stimulation of B and T cells by in vivo high dose immunoglobulin administration in normal mice,” Journal of Autoimmunity, vol. 4, no. 2, pp. 325–339, 1991. View at Publisher · View at Google Scholar · View at Scopus
  41. O. Aktas, S. Waiczies, U. Grieger, U. Wendling, R. Zschenderlein, and F. Zipp, “Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis,” Journal of Neuroimmunology, vol. 114, no. 1-2, pp. 160–167, 2001. View at Google Scholar
  42. M. J. de Grandmont, C. Racine, A. Roy, R. Lemieux, and S. Néron, “Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG,” Blood, vol. 101, no. 8, pp. 3065–3073, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Heidt, D. L. Roelen, C. Eijsink, M. Eikmans, F. H. Claas, and A. Mulder, “Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production,” Clinical and Experimental Immunology, vol. 158, no. 1, pp. 99–105, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Clark, J. Y. Cole, A. Wortley et al., “Intravenous immunoglonulin-induced panel reactive Ab a reduction: not all preparations are created equal,” Transplantation, vol. 75, no. 2, pp. 242–245, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. M. H. Ravindranath, D. Zhu, T. Pham et al., “Anti-HLA-E monoclonal Abs reacting with HLA-la and lb alleles like IVIg as potential IVIg-immunomimetics: an evolving therapeutic concept,” Clinical Transplants, vol. 2013, pp. 293–305, 2013. View at Google Scholar
  46. M. H. Ravindranath, P. I. Terasaki, T. Pham, V. Jucaud, and S. Kawakita, “Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E Abs that react with HLA-Ia (HLA-A/-B/-Cw) alleles,” Blood, vol. 121, no. 11, pp. 2013–2028, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. M. H. Ravindranath, P. I. Terasaki, T. Pham, V. Jucaud, and S. Kawakita, “Suppression of blastogenesis and proliferation of activated CD4 (+) T cells: intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal Abs mimicking HLA-I reactivity of IVIg,” Clinical and Experimental Immunology, vol. 178, no. 1, pp. 154–177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Zhu, M. H. Ravindranath, P. I. Terasaki, T. Miyazaki, T. Pham, and V. Jucaud, “Suppression of allo-human leucocyte antigen (HLA) Abs secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg,” Clinical and Experimental Immunology, vol. 177, no. 2, pp. 464–477, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Glotz, J. P. Haymann, P. Niaudet, P. Lang, P. Druet, and J. Bariety, “Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins,” Transplantation Proceedings, vol. 27, no. 1, pp. 1038-1039, 1995. View at Google Scholar
  50. J. Walknowska, F. A. Conte, and M. M. Grumbach, “Practical and theoretical implications of fetal-maternal lymphocyte transfer,” Lancet, vol. 293, no. 76–6, pp. 1119–1122, 1969. View at Publisher · View at Google Scholar
  51. M. H. Ravindranath, V. Jucaud, C. Y. Maehara, and P. I. Terasaki, “Significance of the differences in the prevalence of anti-HLA Abs in matched pairs of mother's and cord blood,” Immunology Letters, vol. 170, pp. 68–79, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Sbrana, L. Ruocco, R. Vanacore, A. Azzarà, and F. Ambrogi, “In vitro effects of an immunoglobulin preparation for intravenous use (IVIG) on T cells activation,” Allergie et Immunologie (Paris), vol. 25, no. 1, pp. 35–37, 1993. View at Google Scholar
  53. J. Andersson, U. Skansén-Saphir, E. Sparrelid, and U. Andersson, “Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages,” Clinical Experimental Immunology, vol. 104, Supplement 1, pp. 10–20, 1996. View at Google Scholar
  54. P. Chérin and J. Cabane, “Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use,” BioDrugs, vol. 24, no. 4, pp. 211–223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Kivity, U. Katz, N. Daniel, U. Nussinovitch, N. Papageorgiou, and Y. Shoenfeld, “Evidence for the use of intravenous immunoglobulins—a review of the literature,” Clinical Reviews in Allergy & Immunology, vol. 38, no. 2-3, pp. 201–269, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. N. Shehata, V. A. Palda, R. M. Meyer et al., “The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline,” Transfusion Medical Review, vol. 24, Supplement 1, pp. S7–S27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Angulo and D. A. Fulcher, “Measurement of Candida-specific blastogenesis: comparison of carboxyfluorescein succinimidyl ester labelling of T cells, thymidine incorporation, and CD69 expression,” Cytometry, vol. 34, no. 3, pp. 143–151, 1998. View at Publisher · View at Google Scholar
  58. H. Orbach, M. Tishler, and Y. Shoenfeld, “Intravenous immunoglobulin and the kidney—a two-edged sword,” Seminars in Arthritis and Rheumatism, vol. 34, no. 3, pp. 593–601, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. Centers for Disease Control and Prevention (CDC), “Renal insufficiency and failure associated with immune globulin intra-venous therapy—United States, 1985-1998,” MMWR. Morbidity Mortality Weekly Report, vol. 48, no. 24, pp. 518–521, 1999. View at Google Scholar
  60. V. Gras, M. Andréjak, and G. Decocq, “Acute renal failure associated with intravenous immunoglobulins,” Pharmacoepidemiol Drug Safety, vol. 8, Supplement 1, pp. S73–S78, 1999. View at Publisher · View at Google Scholar
  61. H. Orbach, U. Katz, Y. Sherer, and Y. Shoenfeld, “Intravenous immunoglobulin: adverse effects and safe administration,” Clinical Reviews on Allergy Immunology, vol. 29, no. 3, pp. 173–184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. M. C. Dooren, W. H. Ouwehand, A. J. Verhoeven, A. J. Verhoeven, and A. K. von dem Borne, “Adult respiratory distress syndrome after experimental intravenous gamma-globulin concentrate and monocyte-reactive IgG Abs,” Lancet, vol. 352, no. 9140, pp. 1601-1602, 1998. View at Publisher · View at Google Scholar
  63. A. Rizk, K. C. Gorson, L. Kenney, and R. Weinstein, “Transfusion-related acute lung injury after the infusion of IVIG,” Transfusion, vol. 41, no. 2, pp. 264–268, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. P. V. Voulgari, S. Paschou, E. Svarna, N. Tsifetaki, and A. A. Drosos, “Images in rheumatology. Transfusion-related acute lung injury during intravenous immunoglobulin treatment,” Journal of Rheumatology, vol. 37, no. 1, pp. 190-191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. V. Gupta, P. Gupta, and T. P. Yadav, “Transfusion related acute lung injury with intravenous immunoglobulin,” Indian Pediatrics, vol. 48, no. 10, pp. 807-808, 2011. View at Google Scholar
  66. D. R. Reddy, P. K. Guru, M. M. Blessing, J. R. Stubbs, A. A. Rabinstein, and E. F. Wijdicks, “Transfusion-related acute lung injury after IVIG for myasthenic crisis,” Neurocritical Care, vol. 23, no. 2, pp. 259–261, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. R. Kumar, M. J. Sedky, S. J. Varghese, and O. E. Sharawy, “Transfusion related acute lung injury (TRALI): a single institution experience of 15 years,” Indian Journal of Hematology and Blood Transfusion, vol. 32, no. 3, pp. 320–327, 2016. View at Publisher · View at Google Scholar · View at Scopus
  68. P. M. Kopko and P. V. Holland, “Transfusion-related acute lung injury,” British Journal of Haematology, vol. 105, pp. 322–329, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. P. M. Kopko, T. G. Paglieroni, and M. A. Popovsky, “TRALI: correlation of antigen-Ab and monocyte activation in donor-recipient pairs,” Transfusion, vol. 43, no. 2, pp. 177–184, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. U. J. Sachs, “A threshold model for the susceptibility to transfusion-related acute lung injury,” Transfusion Clinical Biology, vol. 19, no. 3, pp. 109–116, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Vo, J. Choi, I. Kim et al., “A phase I/II trial of the interleukin-6 receptor specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients,” Transplantation, vol. 99, no. 11, pp. 2356–2363, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Sethi, J. Choi, M. Toyoda, A. Vo, A. Peng, and S. C. Jordan, “Desensitization: overcoming the immunologic barriers to transplantation,” Journal of Immunology Research, vol. 2017, Article ID 6804678, p. 11, 2017. View at Publisher · View at Google Scholar
  73. V. Nair, D. Sawinski, E. Akalin et al., “Effect of high-dose intravenous immunoglobulin on antiHLA Abs in sensitized kidney transplant candidates,” Clinical Transplantation, vol. 26, no. 3, pp. E261–E268, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Alachkar, B. E. Lonze, A. A. Zachary et al., “Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen Abs in highly sensitized patients,” Transplantation, vol. 94, no. 2, pp. 165–171, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. K. Marfo, M. Ling, Y. Bao et al., “Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients,” Transplantation, vol. 94, no. 4, pp. 345–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Sapir and Y. Shoenfeld, “Facing the enigma of immunomodulatory effects of intravenous immunoglobulin,” Clinical Reviews in Allergy & Immunology, vol. 29, no. 3, pp. 185–199, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. F. Miyagi, H. Horiuchi, I. Nagata et al., “Fc portion of intravenous immunoglobulins suppresses the induction of experimental allergic neuritis,” Journal of Neuroimmunology, vol. 78, no. 1-2, pp. 127–131, 1997. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Klaesson, L. Tammik, L. Markling, I. Lundkvist, and O. Ringden, “Inhibition of immunoglobulin production in vitro by IgG and F(ab’)2 fragments, but not by the Fc portion,” Scandinavian Journal of Immunology, vol. 43, no. 5, pp. 574–582, 1996. View at Publisher · View at Google Scholar
  79. S. Barocci, D. Fenoglio, A. Leprini, and A. Nocera, “Anti-HLA Abs (Ab1) and anti-idiotypic Abs (Ab2) directed against anti-HLA Ab1 in various preparations of polyspecific immunoglobulins for intravenous use,” Bollettino Della Società Italiana Di Biologia Sperimentale (Journal of Biological Research), vol. 66, no. 12, pp. 1193–1200, 1990. View at Google Scholar
  80. M. H. Ravindranath, P. I. Terasaki, C. Y. Maehara et al., “Immunoglobulin (Ig)G purified from human sera mirrors intravenous Ig human leucocyte antigen (HLA) reactivity and recognizes one’s own HLA types, but may be masked by Fab complementarity determining region peptide in the native sera,” Clinical and Experimental Immunology, vol. 179, no. 2, pp. 309–328, 2015. View at Publisher · View at Google Scholar · View at Scopus
  81. R. Luminex, R. Bazin, and A. Neron, “Therapeutic intravenous immunoglobulins,” Molecular Immunology, vol. 42, no. 7, pp. 839–848, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. W. Engelhardt, J. Matzke, and R. E. Schmidt, “Activation-dependent expression of low affinity IgG receptors Fc gamma RII(CD32) and Fc gamma RIII(CD16) in subpopulations of human T lymphocytes,” Immunobiology, vol. 192, no. 5, pp. 297–320, 1995. View at Publisher · View at Google Scholar
  83. F. A. Arosa, S. G. Santos, and S. J. Powis, “Open conformers: the hidden face of MHC-I molecules,” Trends in Immunology, vol. 28, no. 3, pp. 115–123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. P. A. M. Warmerdam, J. G. J. van de Winkel, A. Vlug, N. A. C. Westerdaal, and P. J. A. Capel, “A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding,” Journal of Immunology, vol. 147, no. 4, pp. 1338–1343, 1991. View at Google Scholar
  85. E. Schnabl, H. Stockinger, O. Majdic et al., “Activated human T lymphocytes express MHC class I heavy chains not associated with beta 2-microglobulin,” Journal of Experimental Medicine, vol. 171, no. 5, pp. 1431-1432, 1990. View at Publisher · View at Google Scholar · View at Scopus
  86. J. A. Madrigal, M. P. Belich, R. J. Benjamin et al., “Molecular definition of a polymorphic antigen (LA45) of free HLA-A and -B heavy chains found on the surface of the activated B and T cells,” Journal of Experimental Medicine, vol. 174, no. 5, pp. 1085–1095, 1991. View at Publisher · View at Google Scholar
  87. S. Demaria, R. Schwab, and Y. Bushkin, “The origin and fate of beta 2m-free MHC class I molecules induced on activated T cells,” Cellular Immunology, vol. 142, no. 1, pp. 103–113, 1992. View at Publisher · View at Google Scholar · View at Scopus
  88. W. F. Pickl, W. Holter, J. Stöckl, O. Majdic, and W. Knapp, “Expression of β2-microglobulin-free HLA class I α-chains on activated T cells requires internalization of HLA class I heterodimers,” Immunology, vol. 88, no. 1, pp. 104–109, 1996. View at Publisher · View at Google Scholar
  89. R. L. Allen and J. Trowsdale, “Recognition of classical and heavy chain forms of HLA-B27 by leukocyte receptors,” Current Molecular Medicine, vol. 4, no. 1, pp. 59–65, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. M. H. Ravindranath, H. Kaneku, N. El-Awar, L. E. Morales-Buenrostro, and P. I. Terasaki, “Abs to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-E-positive sera,” Journal of Immunology, vol. 185, no. 3, pp. 1935–1948, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. V. Jucaud, M. H. Ravindranath, and P. I. Terasaki, “Conformational variants of the individual HLA-I antigens on Luminex single antigen beads used in monitoring HLA Abs: problems and solutions,” Transplantation, vol. 101, no. 4, pp. 764–777, 2017. View at Publisher · View at Google Scholar · View at Scopus
  92. M. H. Ravindranath and V. Jucaud, “Conformational variants of HLA-I antigens on Luminex single antigen beads for monitoring Abs,” Transplantation, 2017, (in press). View at Publisher · View at Google Scholar · View at Scopus
  93. S. Le Gall, L. Erdtmann, S. Benichou et al., “Nef interacts with the mu-subunit of clatherin adaptor complexes and reveals a cryptic sorting signal in MHC-I molecules,” Immunity, vol. 8, no. 4, pp. 483–495, 1998. View at Publisher · View at Google Scholar · View at Scopus
  94. G. B. Cohen, R. T. Gandhi, D. M. Davis et al., “The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells,” Immunity, vol. 10, no. 6, pp. 661–671, 1999. View at Publisher · View at Google Scholar · View at Scopus
  95. S. G. Santos, A. N. Antoniou, P. Sampio, S. J. Powis, and F. A. Arosa, “Lack of tyrosine 330 impairs spontaneous endocytosis and enhances release of HLA-B27 molecules,” Journal of Immunology, vol. 176, no. 5, pp. 2942–2949, 2006. View at Publisher · View at Google Scholar
  96. B. C. Guild and J. L. Strominger, “Human and murine class I MHC antigens share conserved serine 335, the site of HLA phosphorylation in vivo,” Journal of Biological Chemistry, vol. 259, no. 14, pp. 9235–9240, 1984. View at Google Scholar
  97. S. Coupel, A. Moreau, M. Hamidou, V. Horejsi, J. P. Soulillou, and B. Charreau, “Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation,” Blood, vol. 109, no. 7, pp. 2806–2814, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Ye, M. Lei, P. Jiang et al., “Demonstration of the IgG Ab repertoire against the bacteria Escherichia coli I Chinese intravenous immunoglobulin,” Journal of Pharmacology and Biomedical Analysis, vol. 133, pp. 8–14, 2017. View at Publisher · View at Google Scholar
  99. E. M. Staley Carruba SS, M. Manning, H. P. Pham et al., “Anti-blood group Abs in intravenous immunoglobulin may complicate interpretation of Ab titers,” American Journal of Transplantation, vol. 16, no. 8, pp. 2483–2486, 2016. View at Publisher · View at Google Scholar · View at Scopus
  100. B. Sakem, K. Matozan, U. E. Nydegger, G. Weigel, A. Griesmacher, and L. Risch, “Anti-red blood cell Abs, free light chains, and anti-phospholipid Abs in intravenous immunoglobulin,” Israel Medical Association Journal, vol. 15, no. 10, pp. 617–621, 2013. View at Google Scholar
  101. F. N. Boctor, M. Bhaskaran, B. Sheahan, W. A. Heaton, and E. Molmenti, “ABO-immunoglobulin G Abs in intravenous immunoglobulin can interfere in ABO-mismatched kidney transplants,” Transfusion, vol. 51, no. 8, pp. 1874-1875, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. H. Bouhlal, D. Martinvalet, J. L. Teillaud et al., “Natural autoAbs to Fcγ receptors in intravenous immunoglobulins,” Journal of Clinical Immunology, vol. 34, Supplement 1, pp. S4–11, 2014. View at Publisher · View at Google Scholar · View at Scopus